Adaptive Biotechnologies’ Split Isn’t a Retreat — It’s a Confession That One Company Can’t Serve Two Masters

Picture the conversation in Adaptive Biotechnologies’ Seattle boardroom sometime in late 2025. On one side of the table, the MRD team is presenting a diagnostics business that generated $145.5 million in revenue in 2024, has an FDA-authorized clonoSEQ assay with a de novo clearance dating to September 2018, and is tracking toward profitability. On the other side, the Immune Medicine team is pitching something fundamentally different: an AI-driven T-cell receptor discovery engine that signed two non-exclusive licensing agreements with Pfizer in December 2025 and anchors what the company describes as the world’s largest immune medicine database. These are not two businesses in productive tension. They are two businesses with different investor audiences, different capital needs, different commercial timelines, and different definitions of what “winning” looks like in five years.

The announcement on June 15, 2026, that Adaptive Biotechnologies would separate its MRD and Immune Medicine businesses reads like a corporate restructuring press release. Strip away the language about “unlocking value” and what it actually says is this: the conglomerate structure was suppressing both businesses, and the board finally admitted it.

That admission is worth taking seriously — because the strategic logic runs deeper than a single company’s portfolio housekeeping.

The Diagnostics Business That Got Stuck Inside a Discovery Company

clonoSEQ is a genuine commercial asset. The assay tracks minimal residual disease in multiple myeloma and B-cell acute lymphoblastic leukemia, giving oncologists a molecular read on whether a patient’s cancer is responding to treatment at a sensitivity level that standard imaging cannot match. The global MRD testing market was valued at $2.50 billion in 2024 and is projected to reach $4.50 billion by 2030, compounding at 10.1% annually. That is a durable growth runway driven by guideline adoption, label expansions, and the broadening of MRD endpoints in regulatory submissions across hematologic malignancies.

Against that backdrop, $145.5 million in 2024 MRD revenue represents real market penetration, not a proof-of-concept. The problem was that Adaptive as a whole reported a net loss of $159.6 million in 2024, with an adjusted EBITDA loss of $80.4 million. Every investor conversation had to carry that weight. Analysts covering the stock had to model two wildly different cash flow profiles simultaneously: a diagnostics franchise approaching profitability and a TCR platform that is years from generating drug revenue. The result was a valuation that satisfied neither the diagnostics-focused comps nor the platform-biotech comps, which meant Adaptive was perpetually trading at a discount to both peer groups.

This is the structural trap that conglomerate biotechs fall into, and it is more common than the industry acknowledges. The market does not reward complexity when the two businesses require opposite narratives to justify their valuations.

Illumina learned this the hard way with GRAIL. After acquiring the liquid biopsy company in 2021 over intense regulatory objection, Illumina’s board voted on June 3, 2024 to complete the spin-off of GRAIL as an independent public entity. The logic was identical: GRAIL’s multi-cancer early detection ambitions required a capital structure, investor base, and narrative arc that Illumina’s sequencing hardware business could not provide without mutual dilution. The separation was not a failure of vision. It was an acknowledgment that vision without focus is just noise, and that capital markets price focus at a premium.

What the Pfizer Deal Reveals About the Real Asset

Here is the counterintuitive read on this separation: the Immune Medicine business may be the more strategically interesting of the two, even though it is the one further from profitability and harder to value.

The December 2025 licensing agreements with Pfizer — one for target discovery, one for immune receptor licensing — signal something specific: Pfizer is paying for access to Adaptive’s TCR map, not for any particular drug candidate. That distinction matters commercially. A deal structured around a discovery platform rather than a named asset suggests Pfizer’s BD team believes the underlying database and AI infrastructure have durable value across multiple therapeutic targets, not just the one on the current slide deck. Platform deals of this structure tend to generate milestone-heavy economics that can be modeled independently once the business is separated from a diagnostics P&L.

The conventional wisdom holds that clinical-stage AI drug discovery platforms are overvalued and underdelivered. Look at the graveyard of first-generation machine learning partnerships that never produced an IND. But Adaptive’s Immune Medicine asset rests on a different foundation: the world’s largest sequenced immune receptor database, built over years of running clonoSEQ tests at clinical scale. The diagnostic business did not just generate revenue. It generated proprietary biological data that now powers the discovery engine. Separating the two entities does not sever that relationship — but it does allow the Immune Medicine company to present that data advantage to investors and partners without the diagnostics revenue being the story they reach for first.

Two Companies, Two Mandates, One Strategic Bet

For the BD and investor community, the practical question is what each entity looks like as a standalone and who the natural acquirers or partners are in each lane.

The MRD diagnostics company is, frankly, an attractive acquisition target for a large laboratory services or genomics platform looking to own a category-defining liquid biopsy franchise. With $145.5 million in revenue, a growing market growing at 10.1% CAGR through 2030, and an FDA-authorized assay already embedded in oncology workflows, this is the kind of asset that Exact Sciences, Guardant Health, or a diagnostics-hungry strategic would seriously evaluate. Freed from the need to fund a parallel drug discovery operation, the MRD business can optimize its commercial infrastructure, pursue guideline expansion aggressively, and present a clean EBITDA story to acquirers or public market investors who want diagnostics exposure without platform biotech risk.

The Immune Medicine entity faces a harder near-term path but a potentially larger ceiling. A focused capital raise post-separation, aimed at institutional investors with an appetite for platform bets in immunology and oncology, becomes possible in a way it was not when Pfizer licensing milestones had to compete for analyst attention with clonoSEQ reimbursement trends. Any mid-cap oncology company evaluating their T-cell therapy pipeline should be watching the Immune Medicine spinout closely: the combination of a curated TCR database and demonstrated willingness to license non-exclusively to a partner like Pfizer suggests a business model built for multiple parallel deals rather than a winner-takes-all internal program.

Adaptive’s board is making a bet that two focused companies, each telling a coherent story to the right investors, will together command more capital and strategic optionality than one muddled conglomerate. Given what happened to Illumina’s stock price when GRAIL sat inside the balance sheet versus the relief rally that followed the 2024 divestiture, that bet has at least one recent data point in its favor.

Back in that Seattle boardroom, the conversation that mattered was not which business was better. It was which structure gave both businesses a real chance. Two teams now get to answer that question with their own capital, their own narrative, and their own mandate. The diagnostics franchise gets to close on profitability without subsidizing a platform play. The platform gets to pitch its Pfizer relationship as the opening line, not the footnote buried beneath a quarterly MRD volume report.

The separation does not resolve the hardest question in biotech portfolio strategy. It simply stops pretending one answer fits both problems.

References

1. Adaptive Biotechnologies via GlobeNewswire — “Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses” (June 15, 2026)
2. BioSpace — Adaptive Biotechnologies MRD revenue and 2024 financial results
3. Grand View Research — “Minimal Residual Disease Testing Market Size Report, 2030” (March 15, 2026)
4. Illumina Investor Relations — “Illumina Completes the Divestiture of GRAIL” (2024)
5. Adaptive Biotechnologies via GlobeNewswire — “Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer” (December 15, 2025)
6. GeekWire — “FDA Approves Adaptive Biotech’s Tool to Track Potential Cancer Relapses” (September 28, 2018)